TCM
LGND icon

Timpani Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Timpani Capital Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-43,461
Closed -$3.68M – 103
2018
Q4 		$3.68M Buy
43,461
+1,134
+3% +$121K 2.06% 11
2018
Q3 		$7.25M Sell
42,327
-3,937
-9% -$594K 2.09% 12
2018
Q2 		$5.98M Buy
46,264
+10,519
+29% +$1.17M 1.77% 13
2018
Q1 		$3.68M Sell
35,745
-210
-0.6% -$20.8K 1.29% 30
2017
Q4 		$3.07M Sell
35,955
-20,349
-36% -$1.76M 1.11% 38
2017
Q3 		$4.78M Buy
56,304
+5,915
+12% +$468K 1.74% 15
2017
Q2 		$3.82M Buy
50,389
+26,203
+108% +$1.83M 1.42% 26
2017
Q1 		$1.6M Sell
24,186
-15,709
-39% -$1.03M 0.64% 68
2016
Q4 		$2.53M Sell
39,895
-74,819
-65% -$4.72M 1.05% 36
2016
Q3 		$7.3M Buy
114,714
+6,545
+6% +$481K 2.9% 2
2016
Q2 		$8.05M Buy
108,169
+154
+0.1% +$11.4K 3.41% 2
2016
Q1 		$7.22M Sell
108,015
-1,245
-1% -$75.7K 3.05% 1
2015
Q4 		$7.39M Buy
109,260
+58,943
+117% +$3.64M 3% 2
2015
Q3 		$2.69M Sell
50,317
-66,785
-57% -$4.05M 1.08% 38
2015
Q2 		$7.37M Sell
117,102
-22,571
-16% -$1.23M 2.14% 7
2015
Q1 		$6.72M Sell
139,673
-3,172
-2% -$122K 2% 9
2014
Q4 		$4.74M Buy
142,845
+76,365
+115% +$2.48M 1.86% 12
2014
Q3 		$1.95M Sell
66,480
-110,341
-62% -$3.66M 0.89% 46
2014
Q2 		$6.87M Buy
176,821
+23,970
+16% +$973K 3.08% 3
2014
Q1 		$6.41M Sell
152,851
-5,775
-4% -$241K 3.39% 1
2013
Q4 		$5.21M Buy
158,626
+32,661
+26% +$1.06M 2.59% 4
2013
Q3 		$3.4M Sell
125,965
-46,765
-27% -$1.32M 2% 16
2013
Q2 		$4.03M Buy
+172,730
New +$3.11M 2.56% 5

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Timpani Capital Management's LGND Position: Q1 2019 in Review

Timpani Capital Management sold out of Ligand Pharmaceuticals (LGND) in Q1 2019, closing a stake of 43,461 shares — an estimated $3.68M sold.

Timpani Capital Management first reported a position in LGND in Q2 2013 and held it in 23 quarters. The position peaked at $8.05M in Q2 2016. 330 funds tracked by Wall St. Rank hold LGND as of Q1 2019.

  • Timpani Capital Management reported no remaining Ligand Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Timpani Capital Management sold 43,461 Ligand Pharmaceuticals shares in Q1 2019, an estimated $3.68M.
  • Timpani Capital Management first reported a position in Ligand Pharmaceuticals in Q2 2013 and held it in 23 quarters.
  • Timpani Capital Management's Ligand Pharmaceuticals position peaked at $8.05M in Q2 2016.
  • 330 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2019.

Based on Timpani Capital Management's 13F filing for Q1 2019, filed 10 May 2019.